Amgen Inc. Fourth Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Amgen, Inc. (NASDAQ:AMGN) will unveil its latest earnings on Thursday, January 26, 2012. Amgen is a biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grave illnesses.

Amgen, Inc. Earnings Preview Cheat Sheet.

Wall St. Earnings Expectations: The average estimate of analysts is for net income of $1.24 per share, a rise of 7.8% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.20. Between one and three months ago, the average estimate moved up. It has dropped from $1.25 during the last month. For the year, analysts are projecting profit of $5.29 per share, a rise of 3.3% from last year.

Past Earnings Performance: Last quarter, the company beat estimates by 12 cents, coming in at net income of $1.38 a share versus the estimate of profit of $1.26 a share. It marked the fourth straight quarter of beating estimates.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: Analysts are projecting a rise of 2.1% in revenue from the year-earlier quarter to $3.92 billion.

Analyst Ratings: 16 out of 25 analysts surveyed (64%) have a buy rating on Amgen.. This is below the mean analyst rating of 10 competitors, which average 71.3% buy ratings.

A Look Back: In the third quarter, profit fell 63.3% to $454 million (50 cents a share) from $1.24 billion ($1.28 a share) the year earlier, but exceeded analyst expectations. Revenue rose 3.4% to $3.94 billion from $3.82 billion.

Key Stats:

Revenue has risen the past four quarters. Revenue rose 4.1% in the second quarter from the year earlier, climbed 3.2% in the first quarter from the year-ago quarter and 0.8% in the fourth quarter of the last fiscal year.

The company has seen net income fall in each of the last three quarters. Net income fell 2.7% in the second quarter and 3.6% in the first quarter.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Biogen Idec Inc. (NASDAQ:BIIB), GlaxoSmithKline plc (NYSE:GSK), Affymax, Inc. (NASDAQ:AFFY), Genzyme Corporation (NASDAQ:GENZ), Roche Holding Ltd. (RHHBY), Novartis AG (NYSE:NVS), 3SBio Inc. (NASDAQ:SSRX), and NPS Pharmaceuticals, Inc. (NASDAQ:NPSP).

Stock Price Performance: During November 21, 2011 to January 20, 2012, the stock price had risen $14.60 (26.6%) from $54.97 to $69.57. The stock price saw one of its best stretches over the last year between December 12, 2011 and December 27, 2011 when shares rose for 11-straight days, rising 12.7% (+$7.26) over that span. It saw one of its worst periods between November 10, 2011 and November 21, 2011 when shares fell for eight-straight days, falling 5.2% (-$2.99) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at